Work

OA12 A Phase I Study of Novel Bcl-2/Bcl-xL Inhibitor APG-1252 in Patients with Advanced SCLC or Other Solid Tumor

Year: 2018

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2018.10.022

Authors: Y. Wu, N.J. Lakhani, M. Boyer, Q. Zhou, D.W. Rasco, Y. Huang, L. Men, Y. Li, Z. Xia, H. Wang, J. Ji, B. Lu, Z. He, Q. Dong, D. Yang, Y. Zhai

Institutions: Chris O’Brien Lifehouse, South Texas Accelerated Research Therapeutics, Ascentage Pharma Group Inc. (United States)

Language: English

Topic: Cell death mechanisms and regulation

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2904937054

Cites:

Cited by: 4

Related to: 10